NASDAQ:BCAB BioAtla (BCAB) Stock Forecast, Price & News $2.00 -0.01 (-0.50%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$1.98▼$2.0550-Day Range$1.95▼$3.0752-Week Range$1.93▼$11.73Volume187,107 shsAverage Volume221,641 shsMarket Capitalization$95.60 millionP/E RatioN/ADividend YieldN/APrice Target$15.33 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioAtla MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside666.7% Upside$15.33 Price TargetShort InterestBearish10.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$5,080 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.82) to ($2.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector552nd out of 961 stocksBiological Products, Except Diagnostic Industry84th out of 157 stocks 3.4 Analyst's Opinion Consensus RatingBioAtla has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.33, BioAtla has a forecasted upside of 666.7% from its current price of $2.00.Amount of Analyst CoverageBioAtla has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.21% of the outstanding shares of BioAtla have been sold short.Short Interest Ratio / Days to CoverBioAtla has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in BioAtla has recently increased by 3.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioAtla does not currently pay a dividend.Dividend GrowthBioAtla does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCAB. Previous Next 1.9 News and Social Media Coverage News SentimentBioAtla has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for BioAtla this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for BCAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows4 people have added BioAtla to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioAtla insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,080.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 8.38% of the stock of BioAtla is held by insiders.Percentage Held by Institutions71.67% of the stock of BioAtla is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioAtla are expected to grow in the coming year, from ($2.82) to ($2.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioAtla is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioAtla is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioAtla has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioAtla (NASDAQ:BCAB) StockBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.Read More BCAB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BCAB Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comBioAtla (NASDAQ:BCAB) versus Cardiol Therapeutics (NASDAQ:CRDL) Head to Head SurveySeptember 6, 2023 | finance.yahoo.comBioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. August 3, 2023 | finance.yahoo.comBioAtla to Participate in Upcoming Investor Conferences in AugustAugust 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioAtla (BCAB), Exelixis (EXEL) and Steris (STE)August 3, 2023 | msn.comJP Morgan Maintains BioAtla (BCAB) Overweight RecommendationAugust 3, 2023 | msn.comJMP Securities Reiterates BioAtla (BCAB) Market Outperform RecommendationAugust 3, 2023 | finance.yahoo.comBioAtla, Inc. (NASDAQ:BCAB) Q2 2023 Earnings Call TranscriptSeptember 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.August 2, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on BioAtla (BCAB)August 1, 2023 | finance.yahoo.comBioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent ProgressJuly 25, 2023 | finance.yahoo.comBioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023July 7, 2023 | finance.yahoo.comWith 51% ownership of the shares, BioAtla, Inc. (NASDAQ:BCAB) is heavily dominated by institutional ownersJuly 6, 2023 | msn.comBioAtla (BCAB) Price Target Increased by 9.33% to 16.73June 26, 2023 | finance.yahoo.comBioAtla Added to Membership of U.S. Small-Cap Russell 2000® IndexMay 31, 2023 | finance.yahoo.comBioAtla to Participate in the Jefferies Healthcare ConferenceMay 16, 2023 | msn.comJMP Securities Reiterates BioAtla (BCAB) Outperform RecommendationMay 15, 2023 | markets.businessinsider.comWhere BioAtla Stands With AnalystsMay 15, 2023 | msn.comHC Wainwright & Co. Reiterates BioAtla (BCAB) Buy RecommendationMay 15, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on BioAtla (BCAB)May 15, 2023 | markets.businessinsider.comBioAtla (BCAB) Receives a Buy from JMP SecuritiesMay 13, 2023 | msn.comEF Hutton Reiterates BioAtla (BCAB) Buy RecommendationMay 12, 2023 | markets.businessinsider.comBioAtla (BCAB) Receives a Buy from BTIGMay 11, 2023 | finance.yahoo.comBioAtla Reports First Quarter 2023 Financial Results and Highlights Recent ProgressMay 11, 2023 | investing.comBioatla (BCAB) Earnings Dates & ReportsMay 8, 2023 | finance.yahoo.comBioAtla to Participate in the JMP Securities Life Sciences ConferenceMay 4, 2023 | finance.yahoo.comBioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023See More Headlines Receive BCAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioAtla and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAB Company Calendar Last Earnings8/01/2023Today9/21/2023Next Earnings (Estimated)11/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCAB CUSIPN/A CIK1826892 Webwww.bioatla.com Phone858-558-0708FaxN/AEmployees66Year FoundedN/APrice Target and Rating Average Stock Price Forecast$15.33 High Stock Price Forecast$25.00 Low Stock Price Forecast$8.00 Forecasted Upside/Downside+666.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-77.19% Return on Assets-58.34% Debt Debt-to-Equity RatioN/A Current Ratio5.21 Quick Ratio5.21 Sales & Book Value Annual Sales$250,000.00 Price / Sales382.42 Cash FlowN/A Price / Cash FlowN/A Book Value$3.79 per share Price / Book0.53Miscellaneous Outstanding Shares47,803,000Free Float43,797,000Market Cap$95.61 million OptionableNot Optionable Beta0.28 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Jay M. Short Ph.D. (Age 65)Co-Founder, CEO & Chairman Comp: $1.06MMr. Richard A. Waldron (Age 69)Sr. VP & CFO Comp: $617.62kDr. Eric L. Sievers M.D. (Age 59)Chief Medical Officer Comp: $608.18kMr. Christian J. Vasquez (Age 47)Sr. VP of Fin., Corp. Controller & Sec. Comp: $408.75kLisa M. PeltonAccounting Mang.Ms. Susie MelodySr. VP of HRDr. Cathy Chang Ph.D.Sr. VP of R&DDr. Gerhard Frey Ph.D.Sr. VP of Technology Devel.Ms. Monica SullivanSr. VP of Intellectual Property & ContractsMs. Sheri LydickChief Commercial OfficerMore ExecutivesKey CompetitorsCidara TherapeuticsNASDAQ:CDTXTurnstone BiologicsNASDAQ:TSBXGenenta ScienceNASDAQ:GNTAJATT AcquisitionNYSE:JATTaTyr PharmaNASDAQ:LIFEView All CompetitorsInsiders & InstitutionsSylvia McbrinnBought 2,000 shares on 9/8/2023Total: $5,080.00 ($2.54/share)California State Teachers Retirement SystemBought 14,714 shares on 8/21/2023Ownership: 0.031%Nuveen Asset Management LLCBought 229,345 shares on 8/16/2023Ownership: 0.480%Goldman Sachs Group Inc.Bought 25,480 shares on 8/15/2023Ownership: 0.172%Wells Fargo & Company MNBought 16,552 shares on 8/15/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions BCAB Stock - Frequently Asked Questions Should I buy or sell BioAtla stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioAtla in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BCAB shares. View BCAB analyst ratings or view top-rated stocks. What is BioAtla's stock price forecast for 2023? 6 Wall Street analysts have issued 12 month price targets for BioAtla's shares. Their BCAB share price forecasts range from $8.00 to $25.00. On average, they expect the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 666.7% from the stock's current price. View analysts price targets for BCAB or view top-rated stocks among Wall Street analysts. How have BCAB shares performed in 2023? BioAtla's stock was trading at $8.25 on January 1st, 2023. Since then, BCAB stock has decreased by 75.8% and is now trading at $2.00. View the best growth stocks for 2023 here. When is BioAtla's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, November 3rd 2023. View our BCAB earnings forecast. How were BioAtla's earnings last quarter? BioAtla, Inc. (NASDAQ:BCAB) released its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.13. What ETF holds BioAtla's stock ? Formidable ETF holds 88,435 shares of BCAB stock, representing 0.77% of its portfolio. When did BioAtla IPO? (BCAB) raised $150 million in an initial public offering (IPO) on Wednesday, December 16th 2020. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies, Credit Suisse and BTIG acted as the underwriters for the IPO. What is BioAtla's stock symbol? BioAtla trades on the NASDAQ under the ticker symbol "BCAB." Who are BioAtla's major shareholders? BioAtla's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.71%), Wasatch Advisors LP (3.15%), Geode Capital Management LLC (1.74%), State Street Corp (1.49%), Renaissance Technologies LLC (1.44%) and Vontobel Holding Ltd. (1.19%). Insiders that own company stock include Christian Vasquez, Cormorant Asset Management, Lp, Eric Sievers, Guy Levy, Jay M Phd Short, Lawrence Steinman, Richard A Waldron, Scott Andrew Smith and Sylvia Mcbrinn. View institutional ownership trends. How do I buy shares of BioAtla? Shares of BCAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioAtla's stock price today? One share of BCAB stock can currently be purchased for approximately $2.00. How much money does BioAtla make? BioAtla (NASDAQ:BCAB) has a market capitalization of $95.61 million and generates $250,000.00 in revenue each year. The company earns $-106,480,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis. How can I contact BioAtla? The official website for the company is www.bioatla.com. The company can be reached via phone at 858-558-0708 or via email at investors@bioatla.com. This page (NASDAQ:BCAB) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioAtla, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.